Company intelligence / Profile preview

Turnstone Biologics

San Diego, California, United Statesturnstonebio.com ↗

Ownership: Public · TSBX
Employees: ~14
Development stage: Other

Overview

Initial data from the STARLING trial showed durable anti-tumor activity in heavily pre-treated microsatellite stable colorectal cancer patients—including a complete response with progression-free survival beyond one year. However, due to capital constraints and manufacturing challenges for its lead program (TIDAL‑01), all clinical development was discontinued in February 2025.

Therapeutic areas: Oncology
Modalities: Tumor-infiltrating lymphocytes (TILs) cell therapyViral immunotherapy platforms
Industry: Biotech

Drug pipeline

13 assets

mg1-magea3

12 more assets in the full pipeline.

Partnerships

Moffitt Cancer Center – investigator-sponsored trials on selected-TIL therapies for melanoma indications

Beyond the preview

Go deeper on Turnstone Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Turnstone Biologics.